Delayed
Australian S.E.
02:10:06 2023-08-24 am EDT
|
5-day change
|
1st Jan Change
|
0.01
AUD
|
-.--%
|
|
-.--%
|
-.--%
|
Fiscal Period: Giugno |
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
76.2
|
26.95
|
16.4
|
-
|
Enterprise Value (EV)
1 |
76.2
|
26.95
|
16.4
|
16.4
|
P/E ratio
|
-4.29
x
|
-140
x
|
-0.42
x
|
-0.27
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
13.9
x
|
44.9
x
|
3.22
x
|
3.22
x
|
EV / Revenue
|
13.9
x
|
44.9
x
|
3.22
x
|
3.22
x
|
EV / EBITDA
|
-3.66
x
|
-0.87
x
|
-0.46
x
|
-0.33
x
|
EV / FCF
|
-
|
-1,262,864
x
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
7,519
|
8,160
|
10,693
|
-
|
Reference price
2 |
10.13
|
3.303
|
1.533
|
1.533
|
Announcement Date
|
8/25/22
|
9/29/23
|
-
|
-
|
Fiscal Period: Junio |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
11.64
|
3.359
|
5.581
|
5.49
|
0.5996
|
5.09
|
5.09
|
EBITDA
1 |
-5.833
|
-1.737
|
-5.74
|
-20.8
|
-30.87
|
-35.8
|
-49.1
|
EBIT
1 |
-7.542
|
-4.18
|
-7.441
|
-21.91
|
-32.02
|
-37.12
|
-58
|
Operating Margin
|
-64.78%
|
-124.43%
|
-133.31%
|
-399.05%
|
-5,340.62%
|
-729.39%
|
-1,139.52%
|
Earnings before Tax (EBT)
1 |
-9.906
|
-6.027
|
-
|
-21.95
|
-32.05
|
-36.67
|
-57.55
|
Net income
1 |
-9.669
|
-7.118
|
-
|
-21.76
|
-31.85
|
-38.66
|
-59.54
|
Net margin
|
-83.05%
|
-211.89%
|
-
|
-396.36%
|
-5,311.01%
|
-759.67%
|
-1,169.8%
|
EPS
2 |
-
|
-
|
-
|
-2.360
|
-0.0236
|
-3.690
|
-5.655
|
Free Cash Flow
|
-15.68
|
-
|
-
|
-
|
-21.34
|
-
|
-
|
FCF margin
|
-134.69%
|
-
|
-
|
-
|
-3,559.36%
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/20/19
|
8/28/20
|
8/25/21
|
8/25/22
|
9/29/23
|
-
|
-
|
Fiscal Period: June |
2020 S1
|
2020 S2
|
2021 S1
|
2021 S2
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2022 S2
|
2023 Q1
|
2023 S1
|
2023 S2
|
2024 S1
|
---|
Net sales
|
4.608
|
1.528
|
6.148
|
-0.5663
|
0.08
|
0.08
|
-0.66
|
-
|
-
|
6.15
|
-
|
0.7395
|
-0.1399
|
-
|
EBITDA
|
-3.88
|
-
|
-3.41
|
-5.93
|
-
|
-
|
-11.11
|
-
|
-
|
-5.57
|
-
|
-
|
-
|
-
|
EBIT
1 |
-5.698
|
1.291
|
-
|
-
|
-5.79
|
-5.79
|
-
|
-3.01
|
-3.01
|
-
|
-7.41
|
-16.3
|
-15.73
|
-
|
Operating Margin
|
-123.66%
|
84.47%
|
-
|
-
|
-7,237.5%
|
-7,237.5%
|
-
|
-
|
-
|
-
|
-
|
-2,203.75%
|
11,245.37%
|
-
|
Earnings before Tax (EBT)
1 |
-6.543
|
0.2891
|
-
|
-
|
-6.57
|
-6.57
|
-
|
-4.4
|
-4.4
|
-
|
-8.16
|
-16.31
|
-15.74
|
-
|
Net income
1 |
-6.364
|
-0.7083
|
-
|
-
|
-6.53
|
-6.53
|
-
|
-4.35
|
-4.35
|
-
|
-8.1
|
-16.21
|
-15.64
|
-15.37
|
Net margin
|
-138.1%
|
-46.34%
|
-
|
-
|
-8,162.5%
|
-8,162.5%
|
-
|
-
|
-
|
-
|
-
|
-2,191.75%
|
11,181.89%
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-0.8260
|
-
|
-0.0142
|
-0.009400
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/20
|
8/28/20
|
2/26/21
|
8/25/21
|
2/23/23
|
2/23/22
|
2/23/22
|
8/25/22
|
8/25/22
|
8/25/22
|
2/23/23
|
2/23/23
|
9/29/23
|
3/15/24
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
3.11
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-0.5338
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-15.7
|
-
|
-
|
-
|
-21.3
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-56.3%
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-16.6%
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
58.17
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.1
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
0.85%
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/20/19
|
8/28/20
|
8/25/21
|
8/25/22
|
9/29/23
|
-
|
-
|
Last Close Price
1.533
AUD Average target price
15.3
AUD Spread / Average Target +897.98% Consensus |
1st Jan change
|
Capi.
|
---|
| -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|